D.E. Shaw & Co
ATRA icon

D.E. Shaw & Co’s Atara Biotherapeutics ATRA Stock Holding History

D.E. Shaw & Co’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-41,360
Closed -$530K – 4334
2023
Q4 		$530K Sell
41,360
-115,057
-74% -$2.68M ﹤0.01% 3487
2023
Q3 		$5.79M Sell
156,417
-17,556
-10% -$781K 0.01% 1692
2023
Q2 		$7M Buy
173,973
+4,781
+3% +$270K 0.01% 1630
2023
Q1 		$12.3M Buy
169,192
+27,912
+20% +$2.71M 0.01% 1213
2022
Q4 		$11.6M Buy
141,280
+32,484
+30% +$3.39M 0.01% 1322
2022
Q3 		$10.3M Buy
108,796
+82,068
+307% +$9.22M 0.01% 1332
2022
Q2 		$5.21M Buy
26,728
+210
+0.8% +$34.3K 0.01% 2077
2022
Q1 		$6.16M Sell
26,518
-10,258
-28% -$3.27M 0.01% 2082
2021
Q4 		$14.5M Buy
36,776
+3,500
+11% +$1.47M 0.01% 1344
2021
Q3 		$14.9M Buy
33,276
+535
+2% +$192K 0.01% 1216
2021
Q2 		$12.7M Buy
32,741
+5,419
+20% +$1.93M 0.01% 1304
2021
Q1 		$9.81M Buy
27,322
+2,936
+12% +$1.3M 0.01% 1370
2020
Q4 		$12M Buy
24,386
+11,590
+91% +$5.35M 0.01% 1272
2020
Q3 		$4.15M Buy
12,796
+916
+8% +$312K ﹤0.01% 1834
2020
Q2 		$4.33M Buy
+11,880
New +$3M 0.01% 1758
2018
Q3 		– Sell
-358
Closed -$329K – 3711
2018
Q2 		$329K Sell
358
-372
-51% -$400K ﹤0.01% 3331
2018
Q1 		$711K Buy
+730
New +$665K ﹤0.01% 2713

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co's ATRA Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Atara Biotherapeutics (ATRA) in Q1 2024, closing a stake of 41,360 shares — an estimated $530K sold.

D.E. Shaw & Co first reported a position in ATRA in Q1 2018 and held it in 17 quarters. The position peaked at $14.9M in Q3 2021. 82 funds tracked by Wall St. Rank hold ATRA as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Atara Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 41,360 Atara Biotherapeutics shares in Q1 2024, an estimated $530K.
  • D.E. Shaw & Co first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 17 quarters.
  • D.E. Shaw & Co's Atara Biotherapeutics position peaked at $14.9M in Q3 2021.
  • 82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.